Modulation of FOXP3 Gene Expression in OVCAR3 Cells Following Rosmarinic Acid and Doxorubicin Exposure

Basit Öğe Kaydı
dc.contributor.authorToprak, Veysel
dc.contributor.authorOzdemir, Ilhan
dc.contributor.authorOzturk, Samil
dc.contributor.authorYanar, Orhan
dc.contributor.authorKizildemir, Yusuf Ziya
dc.contributor.authorTuncer, Mehmet Cudi
dc.date.accessioned2025-01-27T20:49:37Z
dc.date.available2025-01-27T20:49:37Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground/Objectives: Ovarian cancer has the highest mortality rate in the world. Treatment methods are listed as surgery, chemotherapy, and radiotherapy, depending on the stage of cancer, but developing resistance to chemotherapy increases the need for alternative agents that act on the same pathways. The effects of rosmarinic acid (RA) and doxorubicin (DX) on the activation of FOXP3, an important tumor suppressor gene, in OVCAR3 cells were examined. Materials and Methods: In this study, a human ovarian adenocarcinoma cell line was used. MTT analysis was performed to reveal the result of RA and DX on ovarian cancer cell proliferation. Expression levels of FOXP3 for cell proliferation and Capase-3 for apoptosis were determined by RT-qPCR. The wound healing model was applied to determine cell migration rates. The results were evaluated with one-way ANOVA in an SPSS 20.0 program as p <= 0.05. Results: It was determined that RA and DX alone and in combination inhibited the proliferation of OVCAR3 cells in different doses for 24, 48, and 72 h, and caused the cells to die by causing them to undergo apoptosis. Caspase-3 expression increased approximately tenfold in OVCAR3 cells, while FOXP3 expression was upregulated only in RA treatment and was downregulated in DX and RA + DX treatments. Conclusions: According to the results of our study, it was determined that the FOXP3 signaling pathway related to apoptosis, and proliferation was affected by the combination treatment of RA and DX in the OVCAR3 cancer cell line. This shows that RA will gain an important place in cancer treatment with more comprehensive study.
dc.identifier.doi10.3390/ph17121606
dc.identifier.issn1424-8247
dc.identifier.issue12
dc.identifier.pmid39770446
dc.identifier.scopus2-s2.0-85213271584
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/ph17121606
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25251
dc.identifier.volume17
dc.identifier.wosWOS:001383959900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofPharmaceuticals
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectovarian cancer
dc.subjectFOXP3
dc.subjectapoptosis
dc.subjectrosmarinic acid
dc.subjecttumor suppressor
dc.titleModulation of FOXP3 Gene Expression in OVCAR3 Cells Following Rosmarinic Acid and Doxorubicin Exposure
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu